Efficacy and Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials.

Autor: Fulcher, Greg1 greg.fulcher@sydney.edu.au, Mehta, Roopa2, Fita, Edmond G.3, Ekelund, Magnus3, Bain, Stephen C.4
Zdroj: Diabetes Therapy. Feb2019, Vol. 10 Issue 1, p107-118. 12p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje